Summary
Global Markets Direct’s, ‘Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Huntingtin (Huntington Disease Protein) targeted pipeline therapeutics.
The report provides comprehensive information on the Huntingtin (Huntington Disease Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Huntingtin (Huntington Disease Protein) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Huntingtin (Huntington Disease Protein)
- The report reviews Huntingtin (Huntington Disease Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Huntingtin (Huntington Disease Protein) targeted therapeutics and enlists all their major and minor projects
- The report assesses Huntingtin (Huntington Disease Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Huntingtin (Huntington Disease Protein) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Huntingtin (Huntington Disease Protein)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Huntingtin (Huntington Disease Protein) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
AFFiRiS AG
Ionis Pharmaceuticals, Inc.
Neurimmune Holding AG
nLife Therapeutics, S.L.
reMYND NV
Sangamo BioSciences, Inc.
UniQure N.V.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Huntingtin (Huntington Disease Protein) Overview 7
Therapeutics Development 8
Huntingtin (Huntington Disease Protein) - Products under Development by Stage of Development 8
Huntingtin (Huntington Disease Protein) - Products under Development by Therapy Area 9
Huntingtin (Huntington Disease Protein) - Products under Development by Indication 10
Huntingtin (Huntington Disease Protein) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Huntingtin (Huntington Disease Protein) - Products under Development by Companies 13
Huntingtin (Huntington Disease Protein) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Huntingtin (Huntington Disease Protein) - Companies Involved in Therapeutics Development 21
AFFiRiS AG 21
Ionis Pharmaceuticals, Inc. 22
Neurimmune Holding AG 23
nLife Therapeutics, S.L. 24
reMYND NV 25
Sangamo BioSciences, Inc. 26
UniQure N.V. 27
Voyager Therapeutics, Inc. 28
Vybion, Inc. 29
WAVE Life Sciences Ltd. 30
Huntingtin (Huntington Disease Protein) - Drug Profiles 31
AMT-130 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Antisense Oligonucleotide 1 to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
Antisense Oligonucleotide 2 to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Antisense Oligonucleotide to Inhibit HTT for Huntington's Disease - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Gene Therapy to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
INT-41 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
IONIS-HTTRx - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
NI-302 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Small Molecules to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Vaccine to Target Huntingtin for Huntington's Disease - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
VYHTT-01 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Huntingtin (Huntington Disease Protein) - Dormant Projects 45
Huntingtin (Huntington Disease Protein) - Featured News & Press Releases 46
Mar 22, 2016: uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington’s Disease 46
Jan 05, 2016: Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington Disease 46
Jul 21, 2015: Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease 47
Nov 19, 2014: Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms 48
Nov 12, 2013: Sangamo BioSciences Announces Presentation Of First Demonstration Of In Vivo Efficacy Of Novel ZFP Therapeutic For Huntington's Disease 49
Sep 03, 2013: Vybion’s Huntington Drug Neutralizes Critical Disease Driver 51
Oct 17, 2012: Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic For Huntington's Disease At 2012 Annual Meeting Of Society For Neuroscience 51
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54
List of Tables
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Indication, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Action, H1 2016 16
Number of Products by Stage and Route of Administration, H1 2016 18
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by AFFiRiS AG, H1 2016 21
Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 22
Pipeline by Neurimmune Holding AG, H1 2016 23
Pipeline by nLife Therapeutics, S.L., H1 2016 24
Pipeline by reMYND NV, H1 2016 25
Pipeline by Sangamo BioSciences, Inc., H1 2016 26
Pipeline by UniQure N.V., H1 2016 27
Pipeline by Voyager Therapeutics, Inc., H1 2016 28
Pipeline by Vybion, Inc., H1 2016 29
Pipeline by WAVE Life Sciences Ltd., H1 2016 30
Dormant Projects, H1 2016 45
List of Figures
Number of Products under Development for, H1 2016 8
Number of Products under Development by Therapy Area, H1 2016 9
Number of Products under Development by Top 10 Indication, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy/Combination Products, H1 2016 15
Number of Products by Stage and Mechanism of Actions, H1 2016 16
Number of Products by Routes of Administration, H1 2016 17
Number of Products by Stage and Routes of Administration, H1 2016 17
Number of Products by Molecule Types, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 19
